Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817939 | 0.87 | ADAMTS4 (0.43) | PPARAADAMTS4CA12CA1CA2 | |
| SCHEMBL6818391 | 0.86 | CA12 (0.46) | PPARAADAMTS4CA12CA1CA2 | |
| SCHEMBL3117277 | 0.85 | PPARA (0.51) | PPARAADAMTS4CA12CA1CA2 | |
| SCHEMBL21464183 | 0.85 | CA12 (0.46) | ADAMTS4CA12CA1CA2CA9 | |
| SCHEMBL5390555 | 0.85 | CYP17A1 (0.49) | ADAMTS4CA1CA2CYP17A1 | |
| SCHEMBL27167710 | 0.84 | CYP17A1 (0.51) | PPARAADAMTS4CA1CA2CYP17A1 | |
| SCHEMBL6920421 | 0.83 | PPARA (0.48) | PPARAADAMTS4CYP17A1FAAH | |
| SCHEMBL6818248 | 0.80 | PPARA (0.44) | PPARAADAMTS4CA12CA1CA2 | |
| SCHEMBL6818140 | 0.79 | PPARA (0.51) | PPARAADAMTS4CYP17A1 | |
| SCHEMBL6817490 | 0.79 | PPARA (0.51) | PPARAADAMTS4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | claimed |
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARA 74/4885ADAMTS4 4235/4885CA12 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.